Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Cancer Research Horizons: The Innovation Engine of Cancer Research UK

Following ELRIG 2022, News-Medical speaks with Cancer Research Horizons, the innovation engine of Cancer Research UK about their efforts to advance the drug discovery sector.

From Cancer Research UK 14 Nov 2022

Nanotechnology platform can make solid tumor cells more receptive to immunotherapy

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy.

10 Nov 2022

Dogs are a better proxy for human health risks, UQ researchers say

University of Queensland researchers are looking to dog owners for data on protecting pet – and human health – from environmental hazards.

10 Nov 2022

COVID-19 amplifies damage to the central nervous system in Alzheimer's disease

In a recent study published in the journal Annals of Diagnostic Pathology, researchers in the United States evaluated the impact of coronavirus disease 2019 (COVID-19) on central nervous system (CNS) damage in Alzheimer's disease (AD).

7 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

This study is led by Dr. Longtao Huangfu, and Dr. Xiaoyang Wang (Peking University Cancer Hospital & Institute). A diet of fresh fruits and vegetables may reduce the prevalence of cancers, including GC (Eusebi et al., 2020; Liu et al., 2021).

28 Oct 2022

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

28 Oct 2022

Study shows the potential of experimental monoclonal antibodies to treat Epstein-Barr virus infection

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting.

27 Oct 2022

One Medicine: how human and veterinary medicine can benefit each other

News-Medical speaks to Professor Roberto La Ragione, Chair of Trustees at Humanimal Trust, about the concept of One Medicine and how human and veterinary medicine can collaborate, share knowledge, and initiate research for the benefit of both humans and animals.

26 Oct 2022

Researchers streamline way to manufacture CAR T-cells in just 24 hours

Researchers at University Hospitals (UH) Seidman Cancer Center and a biotech start-up company have developed a streamlined way to manufacture CAR T-cells for immunotherapy treatment in just 24 hours – an improvement over the team's previous benchmark of eight days and commercial suppliers that typically take three weeks.

25 Oct 2022

Mayo Clinic scientists awarded $12.1 million NCI grant for breast cancer research

A team of researchers from Mayo Clinic Comprehensive Cancer Center has been awarded a five-year, $12.1 million Specialized Program of Research Excellence (SPORE) grant in breast cancer from the National Cancer Institute.

20 Oct 2022

Physical exercise improves cardiorespiratory fitness, alleviates adverse effects of cancer treatment

During chemotherapy, physical exercise intervention is safe, improves long-term cardiorespiratory fitness, and alleviates some of the adverse effects of cancer treatment, according to a study published in JACC: CardioOncology.

18 Oct 2022

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.

17 Oct 2022

Did the diagnosis and management of Hodgkin lymphoma differ during the SARS-CoV-2 pandemic?

In a new study, researchers evaluated the impact of the SARS-CoV-2 pandemic on the diagnosis and treatment of classical Hodgkin lymphoma (cHL) patients in Istanbul, Turkey.

17 Oct 2022

Epigenetics drug used to treat blood cancers, rare sarcomas can halt bladder cancer growth

An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, reports a new Northwestern Medicine study done in mice.

5 Oct 2022

Research shows higher risk of sexual problems among young women cancer survivors

Young women cancer survivors are at much higher risk of sexual problems including loss of libido and discomfort, according to research published in the peer-reviewed journal Acta Oncologica.

30 Sep 2022

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

Embedded bias: How medical records sow discrimination

David Confer, a bicyclist and an audio technician, told his doctor he "used to be Ph.D. level" during a 2019 appointment in Washington, D.C. Confer, then 50, was speaking figuratively: He was experiencing brain fog — a symptom of his liver problems. But did his doctor take him seriously? Now, after his death, Confer's partner, Cate Cohen, doesn't think so.

26 Sep 2022

What are the effects of pesticides on neonates' health?

A new study explores the impact of pesticide exposure in neonates, reviewing current literature while evaluating the research methods used in this area.

20 Sep 2022

Is aspirin linked to higher rates of survival for cancer patients?

Researchers discussed the existing evidence on the use of acetylsalicylic acid (aspirin) in cancer treatment.

19 Sep 2022